Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

8,491 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Management, outcomes and survival of an Australian IgG4-SC cohort: The MOSAIC study.
Kemp W, Majeed A, Mitchell J, Majumdar A, Tse E, Skoien R, Croagh D, Dev A, Gao H, Weltman M, Craig P, Stuart K, Cheng W, Edmunds S, Lee E, Sood S, Metz A, Thompson A, Sinclair M, Beswick L, Nicoll A, Riordan S, Braund A, Muller K, MacQuillan G, Sandanayake N, Shackel N, Roberts SK. Kemp W, et al. Among authors: cheng w. Liver Int. 2021 Dec;41(12):2934-2943. doi: 10.1111/liv.15036. Epub 2021 Sep 3. Liver Int. 2021. PMID: 34392596
Impact of high-dose peginterferon alfa-2A on virological response rates in patients with hepatitis C genotype 1: a randomized controlled trial.
Roberts SK, Weltman MD, Crawford DH, McCaughan GW, Sievert W, Cheng WS, Rawlinson W, Desmond PV, Marks PS, Yoshihara M, Rizkalla B, Depamphilis JK, Dore GJ; Chariot Study Group. Roberts SK, et al. Among authors: cheng ws. Hepatology. 2009 Oct;50(4):1045-55. doi: 10.1002/hep.23130. Hepatology. 2009. PMID: 19676125 Clinical Trial.
Virological response is associated with decline in hemoglobin concentration during pegylated interferon and ribavirin therapy in hepatitis C virus genotype 1.
Sievert W, Dore GJ, McCaughan GW, Yoshihara M, Crawford DH, Cheng W, Weltman M, Rawlinson W, Rizkalla B, Depamphilis JK, Roberts SK; CHARIOT Study Group. Sievert W, et al. Among authors: cheng w. Hepatology. 2011 Apr;53(4):1109-17. doi: 10.1002/hep.24180. Hepatology. 2011. PMID: 21480317 Clinical Trial.
Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: Analysis from the PREDICT and CHARIOT studies.
Roberts SK, Mitchell J, Leung R, Booth D, Bollipo S, Ostapowicz G, Sloss A, McCaughan GW, Dore GJ, Thompson A, Crawford DH, Sievert W, Weltman M, Cheng W, George J; Australian Liver Association Clinical Research Network. Roberts SK, et al. Among authors: cheng w. J Gastroenterol Hepatol. 2014 Jan;29(1):179-84. doi: 10.1111/jgh.12424. J Gastroenterol Hepatol. 2014. PMID: 24219707
ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response.
Holmes JA, Roberts SK, Ali RJ, Dore GJ, Sievert W, McCaughan GW, Crawford DH, Cheng WS, Weltman MD, Bonanzinga S, Visvanathan K, Sundararajan V, Desmond PV, Bowden DS, Matthews GV, Thompson AJ; CHARIOT Study Group. Holmes JA, et al. Among authors: cheng ws. Hepatology. 2014 Jun;59(6):2152-60. doi: 10.1002/hep.27022. Epub 2014 Apr 25. Hepatology. 2014. PMID: 24449403
FibroGENE: A gene-based model for staging liver fibrosis.
Eslam M, Hashem AM, Romero-Gomez M, Berg T, Dore GJ, Mangia A, Chan HLY, Irving WL, Sheridan D, Abate ML, Adams LA, Weltman M, Bugianesi E, Spengler U, Shaker O, Fischer J, Mollison L, Cheng W, Nattermann J, Riordan S, Miele L, Kelaeng KS, Ampuero J, Ahlenstiel G, McLeod D, Powell E, Liddle C, Douglas MW, Booth DR, George J; International Liver Disease Genetics Consortium (ILDGC). Eslam M, et al. Among authors: cheng w. J Hepatol. 2016 Feb;64(2):390-398. doi: 10.1016/j.jhep.2015.11.008. Epub 2015 Dec 1. J Hepatol. 2016. PMID: 26592354 Free article.
8,491 results